Navigation Links
Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Date:8/19/2007

-- New Phase 3 trial of Genasense(R) seeks to confirm benefit in melanoma

-- New IND filed for clinical-stage product to treat bone disease -- Company regains compliance for NASDAQ Global Markets listing; Genta

common stock to resume trading under "GNTA" symbol in August 2007 -- Named-patient/compassionate-use program for Genasense will continue

during Phase 3 trial

-- Appeal of FDA decision on Genasense NDA in CLL pending

BERKELEY HEIGHTS, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTAD) today announced financial results and corporate highlights for the second quarter ended June 30, 2007.

"Over the past several months, we critically examined our development programs and have concluded that our assets and employees represent a significant value opportunity for shareholders," commented Dr. Raymond P. Warrell, Jr., Genta's Chairman and Chief Executive Officer. "Our lead compound, Genasense(R), has demonstrated improved outcomes for patients with CLL and melanoma, and we plan to pursue plans that will seek global regulatory approvals of this drug. In addition to developing dosing schedules of Genasense that may simplify its administration, we have added a new clinical- stage compound with the announcement of an IND filing for an orally available gallium product to treat accelerated bone loss. We plan to continue ongoing efforts to further diversify the Company's portfolio and leverage our expertise in clinical research."

New Randomized Phase 3 Trial of Genasense plus Dacarbazine in Advanced Melanoma

The Company has announced plans to initiate a new Phase 3 trial, now known as AGENDA: "A Randomized Controlled Trial
'/>"/>

SOURCE Genta Incorporated

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...swire-FirstCall/ -- Arcadia Resources, Inc. (NYSE ...sumer health care services under the Arcadia Healt...o its Board of Directors. Goldsmith will replace ...oard. ,, (Photo: http://www.newscom.com/cg... the Daniel Paul Professor of Government and Direc...
(Date:11/9/2009)...swire-FirstCall/ -- Shire plc (LSE: SHP, Nasda...l company, today announced the availability of I... in pharmacies across the United States for the tr...r ( ADHD ) in children and adolescents ages 6 to...ine, is the first and only nonscheduled alpha-2A r...
(Date:11/9/2009)...PRNewswire-Asia/ -- Chindex International, Inc.,("...American provider of Western,healthcare products a...ay,announced results for the second quarter and fi... 2009. , , Financial Highlights:, -- Revenu...illion, flat on, a year over year basis;, ...
Breaking Medicine Technology:Arcadia Resources Names Stephen Goldsmith to Board of Directors 2Arcadia Resources Names Stephen Goldsmith to Board of Directors 3Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 2Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 3Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 4Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 5Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 6Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 7Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 2Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 3Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 4Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 5Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 6Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 7Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 8Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 9Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 10Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results 11Nurses File Cal OSHA Complaint After Hospital Refuses to Supply Swine Flu Masks for Units with Infected Patients 51699 1Nurses File Cal OSHA Complaint After Hospital Refuses to Supply Swine Flu Masks for Units with Infected Patients 51699 2Nurses File Cal OSHA Complaint After Hospital Refuses to Supply Swine Flu Masks for Units with Infected Patients 51699 3YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 1YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 2YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 3Sartorius Stedim Biotech Partners With Cell Culture Media Specialist SAFC Biosciences 28R 29 to Provide World Class Fluid Management and Liquid Powder 51692 1Sartorius Stedim Biotech Partners With Cell Culture Media Specialist SAFC Biosciences 28R 29 to Provide World Class Fluid Management and Liquid Powder 51692 2Sartorius Stedim Biotech Partners With Cell Culture Media Specialist SAFC Biosciences 28R 29 to Provide World Class Fluid Management and Liquid Powder 51692 3Sartorius Stedim Biotech Partners With Cell Culture Media Specialist SAFC Biosciences 28R 29 to Provide World Class Fluid Management and Liquid Powder 51692 4Sartorius Stedim Biotech Partners With Cell Culture Media Specialist SAFC Biosciences 28R 29 to Provide World Class Fluid Management and Liquid Powder 51692 5
... Effect of Quark,s New RNAi Product on,Dying Retin...a, FREMONT, Calif., Sept. 25 Quark Pharmaceutica...y discovering and developing novel,RNA interferenc...007 as the,Company,s first siRNA drug candidate ba... novel structures having freedom to operate in the...
...wswire-FirstCall/ -- Lotus,Pharmaceuticals, Inc. (..."), a pharmaceutical products developer, manufactu...ina ("PRC"), today announced that,China,s State Fo...e,Company,s drug Laevo-Bambutero for clinical tria...ma, and the Company views,it as a more effective d...
Other Medicine Technology:Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property 2Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property 3Lotus Pharmaceuticals, Inc.'s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials 2Lotus Pharmaceuticals, Inc.'s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials 3
(Date:11/9/2009)..., however , , MONDAY, Nov. 9 (HealthDa...se breasts have a higher risk of cancer recurrence...reast density has already been linked with an incr...s have suspected that very dense breasts may also ...urrence at the site of the original cancer after l...
(Date:11/9/2009)... Abt Associates continues to broaden its experti...ment consulting and support services with three re...e Federal Emergency Management Agency,s (FEMA) Off...n on Children and Disasters and the Washington Met...ue of the combined contracts is approximately $1.5...
(Date:11/9/2009)...e/ -- The American Academy of Physician Assistants...practicing physician assistants (PAs) practicing i...presentatives for passing Saturday its health care...e for America Act. ,, "We are especially deligh...e cost of health care and greatly expand coverage ...
(Date:11/9/2009)..., , Montreal, November 9, 2009 On Noah,s Ark ani...s trillions of cells are coupled, too, and so are ...hese don,t come in twos, they are regrouped into i...ell networks are the backbone of life and illness... cell clusters down to their original pairs. , ...
(Date:11/9/2009)...d suffer from cataracts. Thomas Kohnen of the Goet...ss cataract surgery with the implantation of an ar...zteblatt International ( Dtsch Arztebl Int 2009;...ue to opacification of the lens. In Germany alone,...ed each year. Cataracts can be either congenital o...
Breaking Medicine News(10 mins):Health News:Dense Breasts Raise Risk of Cancer Recurrence 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 3Health News:Abt Associates Expands Emergency Management Support Services To the Federal Government and Washington Metropolitan Area Transit Authority 2Health News:American Academy of Physician Assistants Applauds U.S. House of Representatives for Passing Health Care Reform Bill 2
...t will suffer most under global warming. Past hist...re climate change//. Of greatest concern are the '...hese will have the most devastating effects. In a ...ught that coincided with the harrowing period of M...
... actresses are the true influencers of the "ultra ...ontactmusic.com, Twiggy says thin actresses go on ...sing eating disorders among fans. She wants to see...ost models are naturally long and gangly, while a ...
...e to Britain in 2002 to work in the National Healt... job due to an incurable brain disease, will now b...y a local newspaper in Sunderland. Kaushik C...n elderly care at Sunderland Royal Hospital in Feb...
...utism and related advocacy groups are questioning ...t providing a strategy for laying out// treatment .... Clement, in response has released a series of sm...d and a Families for Early Autism Treatment advoca...
...nsulin production in mice with type 2 diabetes, de...ddress diabetes, say Tulane University gene// ther...his week in the Early Edition of the Proceedings o...ly because of their ability to repair many tissues...
...y cardiologists of Royal Brompton Hospital helps i...ness in heart of young people. The// process invo...tient's vein and then scanning for the results usi...rwise will go undetected. With DCM, the heart is e...
Other Medicine News:Health News:Impact of Climate Change in Africa 2Health News:Ailing Indian doctor in Britain to return to Kolkata 2
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
Medicine Products: